Recruiting
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
J1O-MC-JZHD - ClinicalTrials.gov - NCT04106219
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
How long will I be in the trial?
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Recruiting
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
J1O-MC-JZHD - ClinicalTrials.gov - NCT04106219
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
How long will I be in the trial?
Your participation in this trial could last up to 67 months, depending on your cancer type and how you and your tumor responds.
Key Requirements
Age :
2-21
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-21
Sex
All
Participants must
Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue
Participants must be able to swallow capsules
Participants must NOT
Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant
Participants must not have untreated tumor that has spread to the brain or spinal cord
Participants must not have a serious active disease other than neuroblastoma
Participants must not have a condition affecting absorption
Participants must not have had prior aurora kinase inhibitor exposure
Participants must not have a known allergy to the study treatment
Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C
Trial Summary
Conditions the trial is for
Neuroblastoma, Pediatric Solid Tumors, Pediatric Cancer
What the trial is testing?
LY3295668 Erbumine, Topotecan, Cyclophosphamide
Could I receive a Placebo?
no
Enrollment Goal
71
Trial Dates
June 2020 - April 2025
Trial Phase
1
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
2-21
Sex
All
Participants must
Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue
Participants must be able to swallow capsules
Participants must NOT
Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant
Participants must not have untreated tumor that has spread to the brain or spinal cord
Participants must not have a serious active disease other than neuroblastoma
Participants must not have a condition affecting absorption
Participants must not have had prior aurora kinase inhibitor exposure
Participants must not have a known allergy to the study treatment
Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C
Trial Summary
Conditions the trial is for
Neuroblastoma, Pediatric Solid Tumors, Pediatric Cancer
What the trial is testing?
LY3295668 Erbumine, Topotecan, Cyclophosphamide
Could I receive a Placebo?
no
Enrollment Goal
71
Trial Dates
June 2020 - April 2025
Trial Phase
1
Not the right fit? Sign up to receive updates on new trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Resources
